We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Shield Therapeutics Plc | LSE:STX | London | Ordinary Share | GB00BYV81293 | ORD 1.5P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.10 | -7.55% | 1.225 | 1.20 | 1.25 | 1.325 | 1.075 | 1.33 | 8,963,337 | 13:30:40 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 4.47M | -40.44M | -0.0522 | -0.23 | 9.46M |
Date | Subject | Author | Discuss |
---|---|---|---|
01/3/2021 14:53 | Has this been tipped somewhere ?This is a 33pct premium to the open offer | nico115 | |
01/3/2021 12:49 | @EKCS Thank you. In that case, I'm surprised they agreed to the fundraising rather than insist on a licensing deal, even if it was a bad one. | mirako | |
01/3/2021 12:25 | Might consider buying in again at 37p | volsung | |
01/3/2021 12:19 | @mirako: WHealth is Inventages and vice versa (see IPO docs). They haven't put any money in since exercising warrants in 2017. If they had either pit in or taken out it would have had to be made public and there has never been such an announcement. They are going to take a massive dilution down to about 25% in this fund raising which is probably one of the few good things as it will reduce their power. In contrast it looks like AOP will increase its influence quite significantly if it is heavily subscribing as is suggested, rather than providing the loan that had been previosuly agreed, juicy arrangement fee paid BUT never drawn down!! Schwieger's holding is largely irrelevant in the overall scheme of things and the CEO is only going to account for 1-2 % post close. As nobby says, in the open offer you can apply for upto 13.95m if you're feeling flush or lucky!! What you get above your allownace (2 for 17) will just depend on what others apply for. | ekcs | |
01/3/2021 09:51 | Smithie6 - thanks for your intelligent comment, I had a good chuckle :) Thank goodness the schools go back soon. | pdt | |
01/3/2021 09:34 | PDT "Looking at their December slide pack they believe they can make annual profits at Year 5 of around £100m in the US." You actually believe the predictions for future year 5 income from drug development companies ?!!!! ----- & you realise that 1) the cash raising doc. "needed" to give a high value in order to get ppl to put up hard cash in the cash raise 2) the cash raising doc. is full of disclaimers which basically say that no future prediction should be trusted | smithie6 | |
01/3/2021 08:59 | It's a bit of a gamble to hope to get half your main holding number of shares back that you sold at 50 something on Friday, isn't it Nobby? I would have thought that the majority of us fine folk at £ upwards are going to take their allocation, and also apply for more at 30p .... | daveboy19 | |
01/3/2021 07:31 | Errrrr.....you can apply for any number up to the total available through the open offer so all 13.9 million! I think you have misread the RNS..... | nobbygnome | |
01/3/2021 07:16 | RNS .... u can only apply for extra shares ....Matching the same amount you are entitled to ....So Nobby over to you ... | amaretto1 | |
27/2/2021 16:46 | If there was any chance of a 150p offer being tabled, this 30p raise will have killed it. To be blunt, the raise would never have needed to be so deeply discounted and dilutive, had a more positive mindset to our commercial position existed. For that we know where the blame lies, but what is done, is done. Frankly, I would bite your hand off for 150p at the moment! That said, fortunes can of course turn around. Hopefully this much discussed US sales team have the talent to turn this into a blessing in disguise for us. It would be lovely to look back on this thread in say 12 months time and be able to smile (in a positive, rather than gallows humour way). | lovewinshatelosses | |
27/2/2021 16:11 | Certainly if anyone is circling in the background they could well get it at £1.50 a share it’s certainly the time to pounce | best1467 | |
27/2/2021 11:56 | Anything dodgy and shoddy is involved. | moneymachine2 | |
27/2/2021 09:41 | Maybe I should start reading the bloody RNSs! “......will be used to finance the launch of Accrufer(R) in the US which the Directors believe has the potential to generate significant returns for Shield's shareholders.” No wonder the price held up well. | hodhasharon | |
27/2/2021 09:35 | It's not against the wall now ... imo | amaretto1 | |
27/2/2021 09:34 | Don't rule that out....They could be calling the bidder out !!I'm not really fussed either way The latter would be odviously quicker | amaretto1 | |
27/2/2021 09:28 | I bet we get bid news in a few days. They must have a plan to estimate the funds required to enact that plan. | hodhasharon | |
27/2/2021 09:19 | So looking forward ... Why are u selling at 40 pence ???Pure gambling to get them at 30 Yet they are telling u They don't want u to have them 2/17 | amaretto1 | |
27/2/2021 09:18 | Are u for real ? U have compounded a loss on them ... U r trying to do clever trading ..I'm warning you now .. it won't work !!Believe me. | amaretto1 | |
27/2/2021 09:12 | I actually bought more yesterday and will get as many as I can get in the offer. Looking at their December slide pack they believe they can make annual profits at Year 5 of around £100m in the US. At a multiple of 10 that gives a market cap of £1 billion ignoring any value from Europe and China. However, there is execution risk and say they mess it up and achieve only 50% of those numbers, that's a potential £500m market cap. Today's market value with new shares is around £75m. The risk reward looks good to me and the shares were already discounting a placing when it was announced so I am expecting the share price to remain around 40p in these circumstances. As usual time will tell and I also take the point that the share price often does drift down to the placing price on a raise but I just doubt it in this case. As usual time will tell. | pdt | |
27/2/2021 09:00 | >> amaretto The price I bought them at is completely and utterly irrelevant and I am very surprised you are asking that! As weatherman says above, investing is about looking forward not back! | nobbygnome |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions